Related Experiment Video
Updated: Sep 28, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Genetically engineered T-cells for adoptive immunotherapy
Martin Pule1, Catherine M Bollard, Helen E Heslop
1Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
Adaptive immunotherapy with T-cells is being evaluated as therapy for a number of malignancies and viral infections. Genetic modification of infused T-cells has been used for several years to track such cells, to redirect and augment the immune response towards tumors, and to provide a means of ablating infused T-cells should adverse effects occur. New strategies to target T-cells to tumors and to genetically modify them to make them resistant to tumor evasion mechanisms are being evaluated in preclinical models.
Adaptive immunotherapy with T-cells is being evaluated as therapy for a number of malignancies and viral infections. Genetic modification of infused T-cells has been used for several years to track such cells, to redirect and augment the immune response towards tumors, and to provide a means of ablating infused T-cells should adverse effects occur. New strategies to target T-cells to tumors and to genetically modify them to make them resistant to tumor evasion mechanisms are being evaluated in preclinical models.
